Dowling-Meara Epidermolysis Bullosa Simplex Overview
Learn About Dowling-Meara Epidermolysis Bullosa Simplex
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Lpch Medical Group Div Of Lucile
Joyce Teng is a Dermatologist and a Pediatrics provider in Palo Alto, California. Dr. Teng and is rated as an Elite provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Dowling-Meara Epidermolysis Bullosa Simplex, Dominant Dystrophic Epidermolysis Bullosa, and Liver Embolization.
Mary Spellman is a Dermatologist in San Francisco, California. Dr. Spellman and is rated as an Experienced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Atopic Dermatitis, and Dowling-Meara Epidermolysis Bullosa Simplex.
Permanente Medical Group Inc
Gun Lee is a Dermatologist in Union City, California. Dr. Lee has been practicing medicine for over 5 years and is rated as an Experienced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. His top areas of expertise are Lymphomatoid Papulosis, Dominant Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Epidermolysis Bullosa.
Summary: The goal of this clinical trial is to Assessing the Efficacy and Safety of Apremilast in Patients \> 6 years of age with EB simplex generalized . The main question it aims to answer are: describe efficacity of this treatment. Participants will take treatments and have to use bullets during the study period.
Summary: The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.